The Company announced it submitted a supplemental New Animal Drug Application (NADA) for NOCITA® (bupivacaine liposome injectable suspension) with the U.S. Food and Drug Administration’s Center for Veterinary Medicine (CVM).
The Company plans on presenting at Jefferies 2018 Global Healthcare Conference on Tuesday, June 5, 2018 at 4:30 p.m. ET in New York City.
The Company will participate in two upcoming investor conferences, including the JMP Securities Healthcare Conference and Guggenheim Animal Health Day.
The Company announced that it is currently enrolling patients in two nationwide clinical trials to evaluate its monoclonal antibody for canine T-cell lymphoma, AT-005, which is conditionally licensed by the USDA to aid in the treatment of dogs with lymphoma.
Attendees at ACVIM Forum learned about the Aratana philosophy and got a preview to some of the exciting, innovative products that are in the Aratana pipeline for development.
The Compan announced it has entered into an exclusive license agreement with Vet-Stem, Inc., for its novel, allogeneic stem cell therapy technology.
The Company announced findings from the company’s ongoing safety and clinical programs, which were presented at the 2014 American College of Veterinary Internal Medicine (AVCIM) Forum.
Aratana is proud to call the Kansas City our home. Known as America’s Animal Health Corridor, Kansas City is the global leader for animal health and nutrition research, innovation and production.
Veterinarians stand at both the front line of medicine and the fore front of medical knowledge. Aratana Therapeutics will be at a number of veterinary conferences in the coming months to meet veterinarians interested in learning about the scientific advances we want to bring to pet health.
Aratana Therapeutics is sponsoring two nationwide clinical trials.
June 27, 2013, Aratana filed its initial public offering, validating our unique model and approach to bringing advances in human medical science to pets.
The Company will provide an overview of its business at the Jefferies Global Healthcare Conference and the William Blair Annual Growth Stock Conference.
Aratana Therapeutics – a new kind of animal health company – made their veterinary symposium debut at the 2014 American College of Veterinary Internal Medicine (ACVIM) Forum.
The Company will provide an overview of its business at the Craig-Hallum Institutional Investor Conference and the Stifel Dental & Veterinary Conference.
The Company announced its first quarter 2014 financial results and plans to host a conference call May 13, 2014 at 4:45 p.m. ET.
The Company announced the initiation of the pivotal field effectiveness study for AT-001 (grapiprant), the company’s innovative drug for treating pain in dogs with osteoarthritis.
The Company will host a conference call and live audio webcast on Tuesday, May 13, 2014 at 4:45 p.m. ET to discuss its financial results for the quarter ended March 31, 2014.
The Company announced its presentation plans for the 2014 American College of Veterinary Internal Medicine (ACVIM) Forum to be held June 4-7, 2014 in Nashville.